CorMedix/$CRMD
1D1W1MYTD1Y5YMAX
Capital at risk
About CorMedix
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
- Ticker
- $CRMD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 191
- Headquarters
- Parsippany, United States
- Website
- cormedix.com
CorMedix Metrics
BasicAdvanced
$606M
3.73
$2.08
1.50
-
Price and volume
Market cap
$606M
Beta
1.5
52-week high
$13.02
52-week low
$6.13
Average daily volume
1.3M
Financial strength
Current ratio
2.564
Quick ratio
2.231
Long term debt to equity
0.32
Total debt to equity
0.32
Interest coverage (TTM)
81.68%
Profitability
EBITDA (TTM)
262.548
Gross margin (TTM)
90.21%
Net profit margin (TTM)
40.49%
Operating margin (TTM)
49.16%
Effective tax rate (TTM)
7.98%
Revenue per employee (TTM)
$2,420,000
Management effectiveness
Return on assets (TTM)
24.56%
Return on equity (TTM)
54.93%
Valuation
Price to earnings (TTM)
3.73
Price to revenue (TTM)
1.315
Price to book
1.31
Price to tangible book (TTM)
8.34
Price to free cash flow (TTM)
2.427
Free cash flow yield (TTM)
41.21%
Free cash flow per share (TTM)
3.202
Growth
Revenue change (TTM)
280.50%
Earnings per share change (TTM)
163.53%
3-year revenue growth (CAGR)
2,230.52%
10-year revenue growth (CAGR)
128.95%
3-year earnings per share growth (CAGR)
34.53%
10-year earnings per share growth (CAGR)
-1.75%
What the Analysts think about CorMedix
Analyst ratings (Buy, Hold, Sell) for CorMedix stock.
Analyst projections of the future price of CorMedix stock.
Bulls say / Bears say
CorMedix delivered $101.9 million of second-quarter revenue and $58.7 million of adjusted EBITDA, then raised full-year adjusted EBITDA guidance to $125 million-$140 million. It also ended June with $256.7 million of cash and generated $128.6 million of operating cash flow in the first half. (CorMedix, The Motley Fool)
DefenCath now has commercial supply agreements with all five of the largest US dialysis providers. The newest customer has started ordering and will pilot the product in the third quarter, while larger customers' volumes remained stable after the reimbursement change. (CorMedix, The Motley Fool)
The Melinta acquisition provides an established anti-infective portfolio, while positive Phase 3 ReSPECT data supports a planned REZZAYO filing for prevention of invasive fungal disease. If accepted, the FDA could act in the first half of 2027, giving CorMedix a potential second growth engine. (The Motley Fool, CorMedix)
DefenCath moved from TDAPA reimbursement to the post-TDAPA regime on 1 July, which lowers net pricing and is expected to reduce second-half sales. CorMedix is therefore protecting volumes partly by discounting the product. (CorMedix 10-Q, Investing.com)
The outlook beyond 2026 still depends on decisions CorMedix cannot control, including CMS's 2027 ESRD payment formula and separate Medicare Advantage reimbursement. Management has not included Medicare Advantage revenue in guidance and says meaningful DefenCath volume growth needs that channel or strong uptake from the new dialysis customer. (StockAnalysis, The Motley Fool)
The proposed second growth engine is not yet proven commercially: the REZZAYO prophylaxis application is only expected to be submitted in the third quarter, and FDA action depends on acceptance and review. The DefenCath total-parenteral-nutrition study is not expected to finish until 2028, leaving limited near-term pipeline support. (CorMedix 10-Q, MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
CorMedix Financial Performance
Revenues and expenses
CorMedix Earnings Performance
Company profitability
Upcoming events
No upcoming events
CorMedix News
AllArticlesVideos
Funds containing CorMedix
AllUSDGBPEUR
Fund name | Fund size | $CRMD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.